BriaCell Therapeutics Corp Market Cap ($8.51)
Market Cap & Net Worth: BriaCell Therapeutics Corp (BCTXW)
BriaCell Therapeutics Corp market cap. BriaCell Therapeutics Corp (NASDAQ:BCTXW) has a market capitalization of $8.51 ($8.51) as of November 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #32100 globally and #6498 in its home market, demonstrating a -84.48% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying BriaCell Therapeutics Corp's stock price $0.00 by its total outstanding shares 9453 (9.45K). Also see BriaCell Therapeutics Corp operating cash flow efficiency for how efficiently the company converts equity into cash flow.
BriaCell Therapeutics Corp Market Cap History (2021–2026)
BriaCell Therapeutics Corp market cap history from 2021 to 2026. Data shows change from $44.33K to $8.51 (-73.89% CAGR). Check BriaCell Therapeutics Corp stock quote for real-time trading data and today's change.
BriaCell Therapeutics Corp Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how BriaCell Therapeutics Corp's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore BCTXW year-over-year net asset growth to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of BCTXW by Market Capitalization
Companies near BriaCell Therapeutics Corp in the global market cap rankings as of November 4, 2026. Also see BCTXW asset base for a full breakdown of the balance sheet.
Key companies related to BriaCell Therapeutics Corp by market ranking:
- Arko Corp (NASDAQ:ARKOW): Ranked #32091 globally with a market cap of $25.17 USD.
- Ordinary Fully Paid Deferred Settlement (AU:1TTDB): Ranked #32092 globally with a market cap of $21.00 USD ( AU$29.67 AUD).
- Ucommune International Ltd (NASDAQ:UKOMW): Ranked #32101 globally with a market cap of $6.97 USD.
- immatics biotechnologies GmbH (NASDAQ:IMTXW): Ranked #32102 globally with a market cap of $5.77 USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #32091 | Arko Corp | NASDAQ:ARKOW | $25.17 | $0.00 |
| #32092 | Ordinary Fully Paid Deferred Settlement | AU:1TTDB | $21.00 | AU$0.00 |
| #32101 | Ucommune International Ltd | NASDAQ:UKOMW | $6.97 | $0.00 |
| #32102 | immatics biotechnologies GmbH | NASDAQ:IMTXW | $5.77 | $0.00 |
Market Capitalization of BriaCell Therapeutics Corp (2021–2026)
Market capitalization of BriaCell Therapeutics Corp from 2021 to today. Between 2021 and today, BriaCell Therapeutics Corp's market cap moved from $44.33K to $ 8.51, with a yearly change of -73.89%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $8.51 | -98.30% |
| 2025 | $499.12 | -81.76% |
| 2024 | $2.74K | -88.42% |
| 2023 | $23.63K | +21.37% |
| 2022 | $19.47K | -56.08% |
| 2021 | $44.33K | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of BriaCell Therapeutics Corp was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $8.51 USD |
| MoneyControl | $8.51 USD |
| MarketWatch | $8.51 USD |
| marketcap.company | $8.51 USD |
| Reuters | $8.51 USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About BriaCell Therapeutics Corp
BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that… Read more